CG ONCOLOGY, INC. COMMON STOCK (NASDAQ: CGON)

NASDAQ: CGON (CG Oncology, Inc.)

Kemas kini terakhir: 2 hari lalu, 7:28AM

0.32 (1.22%)

Tambah ke senarai pantauan

Harga / Jualan (P/S)	2.84
Harga / Buku (P/B)	2.91

Julat 52 Minggu	14.80 (-44%) — 40.47 (52%)
Tarikh Pendapatan	13 May 2025

Arah Aliran Pasaran

AISkor Stockmoo

0.4

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
CGON	2 B	-	-	2.91
REPL	781 M	-	-	1.92
GHRS	775 M	-	-	2.50
SANA	656 M	-	-	1.48
PHAT	631 M	-	-	-
ZVRA	499 M	-	-	12.17

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Sektor	Healthcare
Industri	Biotechnology
Gaya Pelaburan	Small Value
% Dimiliki oleh Orang Dalam	1.17%
% Dimiliki oleh Institusi	105.34%

Pemilikan

Nama	Tarikh	Syer Dipegang
Decheng Capital Llc	31 Mar 2025	6,371,669
Foresite Capital Management Vi Llc	31 Mar 2025	2,221,474

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
Morgan Stanley	19 May 2025	52.00 (96.23%)	Beli	24.86
JP Morgan	02 May 2025	41.00 (54.72%)	Beli	29.05
RBC Capital	29 Apr 2025	68.00 (156.60%)	Beli	26.94
Cantor Fitzgerald	28 Apr 2025	75.00 (183.02%)	Beli	27.97
HC Wainwright & Co.	28 Apr 2025	75.00 (183.02%)	Beli	27.97
HC Wainwright & Co.	31 Mar 2025	75.00 (183.02%)	Beli	24.49
Scotiabank	16 Apr 2025	23.00 (-13.21%)	Pegang	20.22

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
05 Jun 2025	Pengumuman	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
15 May 2025	Pengumuman	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
13 May 2025	Pengumuman	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
01 May 2025	Pengumuman	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
26 Apr 2025	Pengumuman	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
24 Apr 2025	Pengumuman	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
31 Mar 2025	Pengumuman	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
28 Mar 2025	Pengumuman	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
24 Mar 2025	Pengumuman	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Portfolio

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Tiada saham yang memenuhi kriteria anda

Margin Operasi (TTM)	-81,161.54%
EPS Cair (TTM)	-1.50
Pertumbuhan Hasil Suku Tahunan (YOY)	-90.20%

Jumlah Hutang/Ekuiti (D/E MRQ)	0.15%
Nisbah Semasa (MRQ)	30.97
Aliran Tunai Operasi (OCF TTM)	-81.98 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-57.18 M

Pulangan Atas Aset (ROA TTM)	-12.85%
Pulangan Atas Ekuiti (ROE TTM)	-16.58%